We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes (The CGM TIME Trial)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01295788
First Posted: February 15, 2011
Last Update Posted: July 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
JDRF Canadian Clinical Trial Network
Juvenile Diabetes Research Foundation
Information provided by (Responsible Party):
Margaret Lawson, Children's Hospital of Eastern Ontario
February 14, 2011
February 15, 2011
July 13, 2017
June 2011
June 2014   (Final data collection date for primary outcome measure)
Adherence to CGM (hours per week) [ Time Frame: one year ]
Number of hours of RT-CGM use per week
Adherence to CGM (hours per week) [ Time Frame: 6 months after RT-CGM initiation ]
Number of hours of RT-CGM use per week
Complete list of historical versions of study NCT01295788 on ClinicalTrials.gov Archive Site
  • A1C [ Time Frame: one year ]
    Hemoglobin A1C
  • Readiness for change [ Time Frame: six months ]
    SOCRATES - Diabetes Version
  • Treatment Satisfaction and Quality of Life [ Time Frame: one year ]
    Insulin Delivery Systems Rating Questionnaire (IDSRQ)
  • Fear of Hypoglycemia [ Time Frame: one year ]
    Hypoglycemia Fear Scale (HFS-98)
  • Barriers to Adherence [ Time Frame: one year ]
    Modified Barriers to Adherence Questionnaire (MBAQ)
  • Perception of Barriers/Facilitators to RT-CGM Use [ Time Frame: one year ]
    CGM Satisfaction Scale (CGM-SAT)
  • Barriers to Adherence [ Time Frame: 0, 3, 6, 9, 12 months ]
    Modified Barriers to Adherence Questionnaire (MBAQ)
  • Readiness for change [ Time Frame: 0 and 6 months ]
    SOCRATES - Diabetes Version
  • Treatment Satisfaction and Quality of Life [ Time Frame: 0, 3, 6, 9, 12 months ]
    Insulin Delivery Systems Rating Questionnaire (IDSRQ)
  • Fear of Hypoglycemia [ Time Frame: 0, 3, 6, 9, 12 months ]
    Hypoglycemia Fear Scale (HFS-98)
  • A1C [ Time Frame: 12 months ]
    1. Mean change in A1C from baseline to 12 months in Simultaneous RT-CGM group compared to delayed RT-CGM group
    2. Proportion of subjects meeting ADA/CDA A1C targets for age at 12 months in Simultaneous RT-CGM group compared to delayed RT-CGM group
    3. Mean change in A1C from baseline to 6 months in Simultaneous RT-CGM group compared to delayed RT-CGM group (ie standard pump therapy)
    4. Proportion of subjects meeting ADA/CDA A1C targets for age at 6 months in Simultaneous RT-CGM group compared to delayed RT-CGM group (ie standard pump therapy)
  • Perception of Barriers/Facilitators to RT-CGM Use [ Time Frame: 0, 6, 12 months ]
    CGM Satisfaction Scale (CGM-SAT)
Not Provided
Not Provided
 
Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes (The CGM TIME Trial)
Simultaneous vs Delayed Initiation of REAL-Time Continuous Glucose Monitoring in Children and Adolescents With Type 1 Diabetes Starting Insulin Pump Therapy
The investigators hypothesize that REAL-Time Continuous Glucose Monitoring (RT-CGM) will be more effective if introduced in children and adolescents with established diabetes at the same time as they are starting pump therapy. This randomized controlled trial will compare the effectiveness of simultaneous vs delayed introduction of RT-CGM in children and adolescents with type 1 diabetes who are starting insulin pump therapy.
REAL-Time Continuous Glucose Monitoring (RT-CGM) improves diabetes control in adults with type 1 diabetes. However, studies of RT-CGM in children and adolescents have been mostly negative. The lack of effectiveness in the pediatric population appears directly related to adherence to RT-CGM, i.e., the willingness of children and teens to wear and use this technology. Most previous RT-CGM studies have focused on experienced pump users or children with new-onset diabetes. At the time of pump initiation, children and adolescents who have been living with diabetes (and their parents) are highly motivated to make changes in their diabetes management and to take on additional responsibilities to improve their diabetes control and lifestyle, the two primary reasons for initiating pump therapy in the pediatric population. The investigators hypothesize that readiness for making changes in diabetes management will be greater at the time of pump initiation than at six months after the pump start. Further, the investigators hypothesize that readiness for change at the time of RT-CGM initiation will predict future adherence to RT-CGM and its effectiveness.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Simultaneous or Delayed initiation of continuous glucose monitoring
Masking: None (Open Label)
Primary Purpose: Treatment
Type 1 Diabetes
  • Device: Simultaneous RT-CGM and Pump Initiation
    Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
    Other Name: Sensor-Augmented Pump Therapy at Pump Initiation
  • Device: Delayed Initiation of RT-CGM
    Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
  • Experimental: Simultaneous RT-CGM and Pump Initiation
    The experimental group will initiate RT-CGM at the same time as they begin insulin pump therapy.
    Intervention: Device: Simultaneous RT-CGM and Pump Initiation
  • Active Comparator: Delayed RT-CGM Initiation
    The control group will use standard pump therapy until the 6 month study visit at which time RT-CGM will be initiated.
    Intervention: Device: Delayed Initiation of RT-CGM

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
144
December 2017
June 2014   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Males and females age 5-18 years old.
  • Established T1D diagnosis for a minimum of one year.
  • Naïve to CSII therapy and ready to start CSII with the Veo pump (Medtronic) .
  • Willing to use RT-CGM and to be randomly assigned to either simultaneous or delayed RT-CGM initiation.
  • Regular diabetes follow up at one of the 5 participating sites.
  • Internet access at home (to upload RT-CGM data).
  • Parent(s) or legally acceptable representative able to speak and read English or French.
  • Ability of the subject and parent(s) or legally acceptable representative to participate in all aspects of this clinical trial.
  • Written informed consent must be obtained and documented, with assent of the child if <14 years of age.

Exclusion Criteria

  • Conditions which in the opinion of the investigator may interfere with the subject's ability to participate in the study.
  • Has received oral and/or intravenous steroid therapy (for any indication, at any dose and/or for any duration) on more than 2 separate occasions in the past 12 months. Use of inhaled and/or topical steroid therapy in the last 12 months does not exclude the subject.
  • Prior use of RT-CGM for more than 50% of the time over the past 6 months.
  • Prior enrollment in the current study.
  • Current enrollment in another intervention trial.
Sexes Eligible for Study: All
5 Years to 18 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01295788
CHEO 09/05E
Yes
Not Provided
Plan to Share IPD: Undecided
Margaret Lawson, Children's Hospital of Eastern Ontario
Children's Hospital of Eastern Ontario
  • JDRF Canadian Clinical Trial Network
  • Juvenile Diabetes Research Foundation
Study Director: Margaret L Lawson, MD Children's Hospital of Eastern Ontario
Children's Hospital of Eastern Ontario
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP